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• Countries are making progress across all WHO
regions in responding to viral hepatitis
• Governments engaged with Civil Society are more
advanced in their national planning efforts
• Financing remains an issuewith aminority of countries
with a national plan having some dedicated funding
• Stronger surveillance and monitoring systems are
needed to direct hepatitis elimination plans
https://doi.org/10.1016/j.jhepr.2019.04.002
Lay summary
TheWorld Health Organization’s goal to eliminate viral
hepatitis as a public health threat by 2030 requires glo-
bal action. Our results indicate that progress is being
made by countries to scale-up national planning
efforts; however, our results also highlight important
gaps in current policies.
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Background & Aims: In 2016, the World Health Assembly passed a resolution to eliminate viral hepatitis as a public health
threat by 2030. We aimed to examine the status of the global viral hepatitis response.
Methods: In 2017, theWorldHealthOrganization (WHO) asked theMinistries ofHealth in all 194Member States to complete a
Country Profile on Viral Hepatitis policy uptake indicators, covering national plans/funding, engagement of civil society, testing
guidance, access to treatment, and strategic information.
Results: Of 194 Member States, 135 (70%) responded, accounting for 87% of the global population infected with hepatitis B
virus (HBV) and/or C virus (HCV). Of those responding, 84 (62%) had developed a national plan, of which, 49 (58%) had dedi-
cated funding, and 62 (46%) had engaged with civil society; those engaged with civil society were more likely to have a funded
plan than others (52% vs. 23%, p = 0.001). Guidance on testing pregnantwomen (forHBV) and peoplewho inject drugs (forHCV)
was available in 70% and 46% of Member States, respectively; 59% and 38% of Member States reported universal access to opti-
mal therapies for HBV and HCV, respectively.
Conclusions:Most people livingwith hepatitis B and C reside in a countrywith a national hepatitis strategy. Governmentswho
engaged with civil society were more advanced in their response. Member States need to finance these national strategies and
ensure that those affected have access to hepatitis services as part of efforts to achieve universal health coverage.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The World Health Organization (WHO) estimates that, in 2015,
viral hepatitis affected around 325 million people worldwide,
with an estimated 257 million cases of chronic hepatitis B virus
(HBV) and 71 million of chronic hepatitis C virus (HCV).1–3 The
WHO also estimated that, in 2015, viral hepatitis (principally
HBV and HCV) caused 1.34 million deaths, mostly from cirrhosis
and hepatocellular carcinoma.1 This death toll is comparable to
that of tuberculosis (1.37 million deaths), and surpasses that of
human immunodeficiency virus (HIV, 1.06 million deaths) and
malaria (0.44 million deaths). While deaths related to HIV,
malaria, and tuberculosis have all declined over the past decade
or more, mortality related to viral hepatitis continues to rise
(22% increase since 2000).1Key words: Public health; global health; viral hepatitis; universal health coverage; HBV;
HCV; direct-acting antivirals.
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E-mail address: Shanley.Smith@nhs.net (S. Smith).In May 2016, the 69th World Health Assembly unanimously
endorsed the first Global Health Sector Strategy (GHSS) on viral
hepatitis.4 The GHSS sets a goal to eliminate viral hepatitis as a
major public health threat, defined as a reduction in i) hepatitis-
related deaths by 65% and ii) new chronic HBV andHCV infections
by 90%, by 2030.Modellingwork highlights thatmajor scale-up of
interventions to prevent transmission, as well as testing and
treatment to prevent the consequences of infection, are needed
to come close to reaching these ambitious targets and eliminating
viral hepatitis.4–6 Treatment is highly effective against HBV and
curative for HCV. However, a comprehensive public health
response is needed to improve access to these interventions if
these targets are to be achieved.6–8
The GHSS lists priority actions for countries to progress their
response to viral hepatitis, including assessment of their epidemio-
logical situation, the development of a national plan with dedi-
cated funding and the setting of targets on intervention coverage
and impact.4 The WHO published a monitoring and evaluation
framework, including 10 core indicators that focus on programma-
tic outcomes, such as coverage of prevention, diagnosis and treat-
ment.9 To monitor progress on these outcomes, countries will
need to invest in the establishment of information systems to
Research Articledeliver on these data.10Meanwhile,we aimed to describe the early
status of WHO Member States in their viral hepatitis response,
focusing on priority actions, plans and processes in place to deliver
on the GHSS. Reporting on interim progress (e.g., to the World




TheWHO contactedMinistries of Health in all 194Member States
through regional and country offices, requesting them to com-
plete an online Country Profile on Viral Hepatitis. The WHO
developed the country profile tool in consultation with the
World Hepatitis Alliance and piloted it with focal points from 3
countries (Morocco, Moldova and Tajikistan). Key items covered
the establishment of national processes and plans on viral hepa-
titis (specifically a focal point, a strategic and technical advisory
group [STAG], a published or drafted national plan, and dedicated
funding), engagement with civil society groups (either as a mem-
ber of the STAG or through other consultations), development of
national testing guidance, access to therapies, and availability of
official working estimates on impact and intervention coverage
targets. We translated the data collection instrument into the 6
official United Nations languages. We uploaded the tool in “EU
Survey”,11 a secure online survey management system. Data col-
lection began in December 2016 and concluded in November
2017. During this period, the WHO regional and country offices
sent reminders electronically. WHO staff also encouraged and
supported participation at relevant viral hepatitis country and
regional meetings.
Data analysis
We tabulated responses according to WHO region (African
Region, Region of the Americas, South-East Asia Region, European
Region, Eastern Mediterranean Region, and Western Pacific
Region) and World Bank income classification (high-income,
upper middle-income, lower middle-income, and low-income).
We compared Member States who reported engagement with
civil society groupswith those who had not, in terms of the status
of their national plan and dedicated funding using the Pearson
Chi-square test with Yates’ continuity correction for categorical
variables. We compared Member States with and without official
working estimates on viral hepatitis mortality in terms of their
report of having set numerical targets for reducing morbidity
and mortality. We compared Member States with and without
official working estimates on treatment coverage in terms of
numerical targets on testing and treatment activities. We esti-
mated the proportion of the global prevalence of HBV and
HCV infection relating to WHO Member States’ responses to
the country profiles using published country level estimates
of the number of people chronically infected with HBV (257
million) and HCV (71 million) in 2015.1–3 We also compared
WHO Member States’ official HCV testing guidance for people
who inject drugs (PWID) by regional groupings from a recent
systematic review on PWID prevalence (East and Southeast Asia,
Eastern Europe, North America, Latin American, Sub-Saharan
Africa, South Asia, Western Europe, Middle East and North Africa,
Central Asia, Australasia, Caribbean, Pacific Island States and
Territories) according to the estimated number of PWID in each
region.12 We analysed data using Microsoft Excel 2010 and
STATA 13.0.JHEP Reports 201For further details regarding the materials used, please refer to
the supplementary CTAT table.
Results
Response
Between December 2016 and November 2017, 135 Member
States (70%) completed their WHO viral hepatitis country pro-
files, accounting for 87% of those infected with HBV or HCV
globally (Fig. 1). Responses ranged from 54% in the Region of
the Americas to 87% in the European Region. The proportion
of the regional burden of viral hepatitis accounted for by partici-
pating Member States exceeded the regional response proportion
in all WHO regions, except in Europe (87% of response, relating to
only 61% of the regional burden, Fig. 1). There was a relatively
even distribution of responses (range 65–79%) according to
income category (Table 1).
National plan and dedicated funding
Most responding Member States (63%) had developed a national
viral hepatitis plan, which was in drafted (27%) or published
(36%) form (Table 1). These Member States accounted for 71% of
individuals infected with HBV or HCV. The proportion of Member
States who had developed a plan ranged from 50% within the
South-East Asia region to 88% in the Eastern Mediterranean
region, and from 46% within low-income settings to 71% in
high-income settings.
While the majority of WHO Member States had developed a
plan (62%), only 37% of respondents had dedicated funding for
implementation (58% of those with a plan developed). The 49
countries dedicating funding to implementation accounted for
18% of individuals infected with HBV or HCVworldwide. The pro-
portion of WHO Member States reporting dedicated funding
ranged from 22% within the African region to 44% in the Eastern
Mediterranean region, and from 25% within low-income settings
to 42-43% in lower middle to high-income settings.
Engagement with civil society
Of WHO Member States, 46% reported engagement with civil
society, either as an official member of the government’s STAG
or other official working group (30%) or through wider consulta-
tion on their response to viral hepatitis (16%, Table 1). The pro-
portion of Member States reporting engagement with civil
society ranged from 47% within the Western Pacific Region to
63% in the Americas and South-East Asia regions, and from 38%
within upper middle-income settings to 54% in high-income
settings. Compared with others, Member States that engaged
civil society were more likely to have national viral hepatitis
plans (84% vs. 44%, p <0.001), to have assigned dedicated funding
(52% vs. 23%, p = 0.001), and to have officially observed World
Hepatitis Day in 2016 (85% vs. 47%, p <0.001). Member States
engaged with civil society were slightly more likely to have
laws or policies on stigma and discrimination, compared to
other Member States (79% vs. 71%, p = 0.4, Fig. 2).
Monitoring and targets
FewMember States reported having official working estimates on
key monitoring and evaluation indicators for HBV and HCV as of
2017. For either HBV or HCV infection, 24–25% of responding
Member States reported having official working estimates on
mortality and 31–34% on incidence of new infection (i.e.measures
of impact). Eight to 23% of responding Member States reported9 vol. 1 | 81–89 82
WHO region
(Total number of Member States)
Map key Member States responding to
viral hepatitis country profile
n (% of N)
Estimated size of the chronic
viral hepatitis (HBV
and HCV) population
Proportion of the estimated viral
hepatitis population with
country profile responses
African region (N = 47) 27 (58%) 67 million 74%
Region of the Americas (N = 35) 19 (54%) 13 million 86%
Eastern Mediterranean Region (N = 21) 16 (76%) 36 million 95%
European Region (N = 53) 46 (87%) 30 million 61%
South-East Asia Region (N = 11) 8 (73%) 49 million 82%
Western Pacific Region (N = 27) 19 (70%) 129 million 99%
Global (N = 194) 135 (70%) 325 million 87%
Fig. 1. WHOMember States providing viral hepatitis country profile responses, 2016-2017. (n = 135, 70% of all WHOMember States and 87% of the 325 million
persons infected with viral hepatitis globally). 1Univariate comparisons using the Pearson Chi-square test with Yates’ continuity correction for categorial variables.
WHO, World Health Organization.having official working estimates on either extent of diagnosed
infection, treatment uptake or response to therapy for either
HBV or HCV infection. Approximately half of responding Member
States reported having official working estimates on prevalence
of infection for HBV (56%) and HCV (51%). The availability of
working estimates on key monitoring and evaluation indicators
varied by WHO region and income classification (Appendix 1.1).
Most Member States in the African, Americas and South-East
Asia regions reported that they lacked working estimates on
impact and intervention coverage indicators.
Around a quarter (27%) of responding Member States reported
having numerical targets for reducingmorbidity (incidence and/or
prevalence) or mortality (death) attributable to HBV and/or HCV
(Table 1). However, only 50% and 56% of those Member States
that reported having set a target on morbidity/mortality also
reported having an official working estimate on mortality attribu-
table to either HBV orHCV, respectively (Appendix 1.2).While 48%
of responding Member States reported having numerical targets
for activities to prevent or treat HBV and/or HCV (Table 1), few of
these Member States reported also having official working esti-
mates on, for example, treatment coverage for HBV (25%) and
HCV (39%, Appendix 1.3).
Testing guidance
Most respondingMember States had official guidance onHBV test-
ing, which included guidance on the diagnostic test to use (69%),JHEP Reports 201testing of pregnant women (70%), and a protocol for referral to
treatment and care following diagnosis (64%). HBV testing gui-
dance varied greatly by WHO region and income classification
(Table 2). The proportion of responding Member States reporting
guidance for testing pregnant women for HBV ranged from
33% in low-income to 93% in high-income settings (p <0.001,
Table 2). Overall, we estimated that 65% of people living with
chronic HBV infection (166 million) resided in a country with
guidance on testing pregnant women for HBV (Table 2).
The majority of responding Member States had official
guidance on HCV testing (64%) and protocols for referral to treat-
ment and care (62%). However, only 46% of responding Member
States had official guidance on testing PWID for HCV (Table 3);
ranging from 11% in the African region to 72% in the European
Region, and from 13% in low-income to 68% in high-income
settings. In 2 regions with particularly high numbers of PWID,
Latin America (1.8 million) and Sub-Saharan Africa (1.4 million),
less than 20% of WHO Member States had guidance on testing
PWID for HCV (Table 4).
Access to treatment
The majority of responding WHO Member States (59%) reported
tenofovir or entecavir to be the first-line treatment for eligible
patients with chronic HBV monoinfection, which accounted for
74% of the global chronic HBV infected population. This varied
from 44% in the African region to 74% in the American region,9 vol. 1 | 81–89 83
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Total number 194 (100%) 135 (70%) 102 (75%) 71 (52%) 62 (46%) 40 (30%) 84 (62%) 48 (36%) 49 (36%) 36 (27%) 65 (48%)
By WHO region:
Eastern Mediterranean 21 (11%) 16 (76%) 14 (88%) 12 (75%) 9 (56%) 4 (25%) 14 (88%) 6 (38%) 7 (44%) 6 (38%) 10 (63%)
Western Pacific 27 (14%) 19 (70%) 17 (90%) 12 (63%) 9 (47%) 7 (37%) 12 (63%) 7 (37%) 7 (37%) 6 (32%) 10 (53%)
Americas 35 (18%) 19 (54%) 13 (68%) 10 (53%) 12 (63%) 4 (21%) 10 (53%) 5 (26%) 7 (37%) 6 (32%) 8 (42%)
South-East Asia 11 (6%) 8 (73%) 6 (75%) 4 (50%) 5 (63%) 1 (13%) 4 (50%) 4 (50%) 3 (38%) 2 (25%) 5 (63%)
European 53 (27%) 46 (87%) 34 (74%) 23 (50%) 24 (52%) 14 (30%) 30 (65%) 21 (46%) 19 (41%) 12 (26%) 24 (52%)
African 47 (24%) 27 (58%) 18 (67%) 10 (37%) 13 (48%) 10 (37%) 14 (52%) 5 (19%) 6 (22%) 4 (15%) 8 (30%)
By income classification:
High 52 (27%) 41 (79%) 33 (81%) 23 (56%) 22 (54%) 14 (34%) 29 (71%) 19 (46%) 17 (42%) 15 (37%) 24 (58%)
Upper-middle 49 (25%) 32 (65%) 25 (78%) 23 (72%) 12 (38%) 9 (28%) 21 (66%) 11 (34%) 10 (31%) 8 (25%) 16 (50%)
Lower-middle 50 (26%) 35 (70%) 30 (86%) 16 (46%) 18 (51%) 9 (26%) 22 (63%) 15 (43%) 15 (43%) 10 (29%) 17 (49%)
Low 34 (18%) 24 (71%) 11 (46%) 7 (29%) 10 (42%) 8 (33%) 11 (46%) 3 (13%) 6 (25%) 2 (8%) 6 (25%)
n.a. 9 (5%) 3 (33%) 3 (100%) 2 (67%) 0 (0%) 0 (0%) 1 (33%) 0 (0%) 1 (33%) 1 (33%) 2 (67%)
Estimated number of people
living with chronic viral
hepatitis in millions
325 (100%) 284 (87%) 241 (74%) 106 (32%) 110 (34%) 66 (20%) 229 (71%) 76 (23%) 58 (18%) 68 (21%) 220 (68%)
CV, civil society; HBV, hepatitis B virus; HCV, hepatitis C virus; MS, Member States; WHO, World Health Organization.
1Strategic and technical advisory group (STAG) is responsible for assessing the hepatitis burden in their country and using evidence to inform their recommendations.
2Civil society is either an official member of the STAG or has otherwise been consulted.
3Numerical targets set for reducing morbidity (incidence and/or prevalence) or mortality (death) attributable to HBV and/or HCV.
4Numerical targets set for activities to prevent or treat HBV and/or HCV.
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Fig. 2. Association between viral hepatitis indicators (including having a
national plan, a plan with dedicated funding, observed World Hepatitis
Day, and laws/policies on stigma and discrimination) and engagement
with civil society as reported by responding Member States1. 1Univariate
comparisons using the Pearson Chi-square test with Yates’ continuity
correction for categorial variables. MS, Member States.
Table 2. Proportion of responding Member States reporting having HBV testin
treatment/care) and the use of optimal therapies in first-line treatment for HB
HBV testing guidance which cove
HBV diagnostic




n (% of N)
Total responding Member States
(N = 135)
93 (69%) 95 (70%)
By WHO region:
Eastern Mediterranean (16) 14 (88%) 9 (56%)
Western Pacific (19) 14 (75%) 13 (68%)
Americas (19) 15 (79%) 14 (74%)
South-East Asia (8) 5 (63%) 6 (75%)
European (46) 33 (72%) 40 (87%)
African (27) 12 (44%) 13 (48%)
By income classification:
High (41) 31 (76%) 38 (93%)
Upper-middle (32) 29 (91%) 25 (78%)
Lower-middle (35) 21 (60%) 21 (60%)
Low (24) 10 (42%) 8 (33%)
n.a. (3) 2 (67%) 3 (100%)
Estimated number of people living with
chronic HBV in millions (257)
147 (57%) 166 (65%)
HBV, hepatitis B virus; WHO, World Health Organization.
1e.g. restrictions on who receives treatment based on disease stage or risk group.
JHEP Reports 201and from 38% in low-income to 73% in high-income settings.
Access to tenofovir or entecavir was prioritized for select patients
in 22% of Member States and not available at all as first-line treat-
ment in 19% of Member States (Table 2).
A minority of responding Member States (38%) reported
direct-acting antiviral (DAA) regimens as first-line treat-
ment for all patients with chronic HCV, which accounted
for 49% of the global chronic HCV infected population.
This varied from 26% in the African region to 56% in the
Eastern Mediterranean region, and from 29% in low-income
to 46% in lower middle-income settings. DAA regimens were
prioritized for select patients in 30% of Member States and
not yet available as first-line treatment in 33% of Member
States (Table 2).
Discussion
The country profiles generated for 135Member States, home to 87%
of the infected population, describe the status of the global response
to viral hepatitis B and C. First, the number of countries with a
national viral hepatitis plan reached 84 in 2017, though only 58%
of countries with a plan had assigned dedicated funding for imple-
mentation. Second, findings that the majority of countries have
guidance on diagnostic testing (69% for HBV and 64% for HCV)
and on referral pathways for treatment and care (64% for HBV
and 62% for HCV) suggest that countries are progressing with
their national response to viral hepatitis. Third, the availability of
data for decision-making remains limited with only a minority of
Member States having working estimates on mortality (24% for
HBV and 25% HCV) and transmission (34% for HBV and 31% forg guidance (covering diagnostic tests, pregnant women, and referral to
V.
rs the following: Tenofovir or entecavir considered first-line
treatment for the following:
Referral to
treatment/care,
n (% of N)
All patients,




n (% of N)
Not first
line,
n (% of N)
87 (64%) 80 (59%) 29 (22%) 26 (19%)
9 (56%) 10 (63%) 2 (13%) 4 (25%)
12 (63%) 12 (63%) 3 (16%) 4 (21%)
14 (74%) 14 (74%) 3 (16%) 2 (11%)
5 (63%) 4 (50%) 4 (50%) 0 (0%)
36 (78%) 28 (61%) 11(24%) 7 (15%)
11 (41%) 12 (44%) 6 (22%) 9 (33%)
32 (78%) 30 (73%) 7 (17%) 4 (10%)
27 (84%) 17 (53%) 9 (28%) 6 (19%)
19 (54%) 22 (63%) 6 (17%) 7 (20%)
6 (25%) 9 (38%) 6 (25%) 9 (38%)
3 (100%) 2 (67%) 1 (33%) 0 (0%)
58 (22%) 109 (74%) 21 (8%) 13 (5%)
9 vol. 1 | 81–89 85
Table 3. Proportion of responding Member States reporting having HCV testing guidance (covering diagnostic tests, PWID, and referral to treatment/care)
and the use of optimal therapies in first-line treatment for HCV.
HCV Testing guidance which covers the following: Interferon-free direct-acting antiviral
regimens considered the first line of treatment
for the following:
HCV diagnostic
test, n (% of N)
HCV testing
of PWID,
n (% of N)
Referral to
treatment/care,
n (% of N)
All patients,




n (% of N)
No,
n (% of N)
Total responding Member States
(N = 135)
87 (64%) 62 (46%) 84 (62%) 51 (38%) 40 (30%) 44 (33%)
By WHO region:
Eastern Mediterranean (16) 15 (93%) 10 (63%) 12 (75%) 9 (56%) 3 (19%) 4 (25%)
Western Pacific (19) 12 (63%) 8 (42%) 11 (58%) 7 (37%) 2 (11%) 10 (53%)
Americas (19) 12 (63%) 4 (21%) 11 (58%) 6 (32%) 3 (16%) 10 (53%)
South-East Asia (8) 5 (75%) 4 (50%) 5 (63%) 4 (50%) 3 (38%) 1 (13%)
European (46) 33 (72%) 33 (72%) 38 (83%) 18 (39%) 22 (48%) 6 (13%)
African (27) 9 (33%) 3(11%) 7 (26%) 7(26%) 7 (26%) 13 (48%)
By income classification:
High (41) 30 (73%) 28 (68%) 33 (81%) 17 (42%) 21 (51%) 3 (7%)
Upper-middle (32) 26 (81%) 13 (41%) 24 (75%) 10 (31%) 9 (28%) 13 (41%)
Lower-middle (35) 19 (54%) 15 (43%) 19 (54%) 16 (46%) 4 (11%) 15 (43%)
Low (24) 10 (42%) 3 (13%) 5 (21%) 7 (29%) 5 (21%) 12 (50%)
n.a. (3) 2 (67%) 3(100%) 3 (100%) 1 (33%) 1 (33%) 1 (33%)
Estimated number of people living
with chronic HCV in millions (71)
46 (64%) 38 (53%) 48 (68%) 35 (49%) 11 (16%) 11 (16%)
HCV, hepatitis C virus; PWID, people who inject drugs; WHO, World Health Organization.
1e.g. restrictions on who receives treatment based on disease stage or risk group.
Research ArticleHCV). A review of the progress reported by governments and the
gaps remaining in national responses highlight the next steps
needed to deliver on the GHSS and its goal of viral hepatitis
elimination.4
National plans for hepatitis constitute the necessary first step
towards action. Compared with 2012 data13 the 2017 country
profiles suggest a 5-fold increase in the number of countries
with national plans. The following factors may explain this
increase: (1) 3 World Health Assembly resolutions that consecu-
tively called for (i) action against hepatitis (2010),14 (ii) consid-
eration of elimination (2014),15 and (iii) global targets for
elimination (2016);16 (2) WHO guidance on the formulation of
national plans (2015);17 (3) the GHSS, which articulates the
need for countries to develop evidenced-based national plans
with a budget to achieve the goal of elimination;4 (4) interna-
tional civil society partners, such as the World Hepatitis Alliance,
that help to link policy vision with patient advocates within
countries.18
The findings of this study highlight the importance of civil
society involvement, as it shows that countries that actively
involve civil society in their hepatitis response are more likely
to have a national plan as well as dedicated domestic funding
for implementation. However, financing remains a serious
concern as dedicated national funding for implementation
was only available in 58% of Member States with national
plans (relating to an estimated 18% of the global infected
population). Countries making the most progress towards
elimination are ones that have national plans with dedicatedJHEP Reports 201funding.19 Additionally, GHSS emphasizes that the global
hepatitis response should involve an enabling environment
of policies and laws that aim to reduce stigma and discrimina-
tion.4 Our analysis showed that the majority (75%) of coun-
tries reported having laws or policies that addressed stigma
and discrimination in general; although, few (7%) countries
had laws or policies specific to viral hepatitis. A recent global
survey of civil society organizations, which aimed to explore
how stigma and discrimination affects those living with viral
hepatitis, found that only 4% of 156 respondents across 72
countries felt that their government was satisfactorily
addressing stigma and discrimination.18 Legal, institutional
and other barriers can impede access to prevention, diagnosis
and treatment services, particularly for those populations at
heightened risk of hepatitis infection (including PWID, men
who have sex with men, prisoners and sex workers).20 Coun-
tries need to reform laws, policies and regulations that
impede equitable access to hepatitis services, and adapt
models of service delivery to meet the needs of affected
populations.4–6
Scaling up testing and treatment of HBV and HCV infection
is fundamental to reducing mortality as part of the GHSS
elimination goal.4–6 WHO guidelines on treatment have been
available since 2014 for HCV infection21 (with updates in
201622 and 201823; the latter recommended treatment for all
those living with HCV infection [except pregnant women] regard-
less of age, risk group or disease stage) and 2015 for HBV infec-
tion,24 while viral hepatitis testing guidelines were published in9 vol. 1 | 81–89 86
Table 4. Responding Member States with HCV testing guidance for PWID, by region and ranked according to estimated number of PWID.1
Region
(N1 = number of countries within region)1
Estimated number of PWID
(95% UI)1
Population prevalence
of PWID (95% UI)1
Responding
Member States




N3 (% of N2)
East and Southeast Asia (16) 3,989,000 (3,041,000–4,955,000) 0.25% (0.19–0.31) 15 (94%) 8 (53%)
Eastern Europe (17) 3,020,000 (1,653,500–5,008,000) 1.30% (0.71–2.15) 14 (82%) 10 (71%)
North America (2) 2,557,000 (1,498,500–4,428,000) 1.06% (0.62–1.83) 2 (100%) 2 (100%)
Latin American (20) 1,823,000 (1,392,000–2,380,000) 0.46% (0.35–0.60) 12 (60%) 2 (17%)
Sub-Saharan Africa (47) 1,378,000 (645,500–3,080,000) 0.28% (0.13–0.62) 27 (58%) 3 (11%)
South Asia (9) 1,023,500 (783,500–1,263,000) 0.09% (0.07–0.11) 6 (67%) 4 (67%)
Western Europe (28) 1,009,500 (686,500–1,386,500) 0.34% (0.23–0.47) 24 (86%) 19 (79%)
Middle East and North Africa (21) 349,500 (177,500–521,500) 0.12% (0.06–0.18) 17 (81%) 9 (53%)
Central Asia (5) 281,500 (189,500–416,500) 0.63% (0.43–0.94) 5 (100%) 3 (60%)
Australasia (2) 115,500 (83,000–148,000) 0.59% (0.42–0.75) 2 (100%) 2 (100%)
Caribbean (13) 79,500 (53,000–118,000) 0.44% (0.30–0.66) 5 (39%) 0 (0%)
Pacific Island States and Territories (12) 22,500 (15,000–33,500) 0.33% (0.22–0.49) 6 (50%) 0 (0%)
Global (194) 15,648,000 (10,219,000–23,737,500) 0.33% (0.21–0.49) 135 (70%) 62 (46%)
HCV, hepatitis C virus; PWID, people who inject drugs; WHO, World Health Organization.
1Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV,
HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal. 2017. 5:e1192-207.2017.25 The country profiles indicate that themajority of countries
report having policies on testing, but these are not necessarily
comprehensive. Important gaps were revealed in policies on
testing of key populations, with (i) low-income countries less
likely to have guidance for testing pregnant women for HBV
(33%) compared to high-income countries (93%), and (ii) many
countries not having specific guidance for testing PWID for HCV,
both overall (73 of 135 countries, 54%) and in the 5 regions (45
of 70 countries, 64%) with the largest share (82%) of the globally
estimated 15.6 million PWID. Routine testing of pregnant
women for HBV, particularly in settings with intermediate or
high HBV surface antigen seroprevalence, and PWID for HCV are
integral to both primary and secondary prevention efforts, and
thus countries need to recognise and integrate these population
groups into their testing policies.4–6,24,25
Many countries reported limited access to optimal HBV and
HCV therapies in 2017. For HBV, only 59% of countries reported
access to tenofovir or entecavir as first-line treatment for all eligi-
ble patients, and for HCV, only 38% reported access to interferon-
free DAA regimens as first-line treatment for all patients. The
price of medicines has been an obstacle to treatment but that is
becoming less of an issue. For example, the price for a year of teno-
fovir treatment for HBV infection using generic medicine was 32
USD in 2016.26 Further, starting in 2018, tenofovir is no longer
protected by patents, meaning all countries can use generic med-
icines. In 2017, 62% of people infected with HCV lived in countries
where genericmedicines could be accessed for around 150USD or
less for a course of treatment.27 Globally, uptake of treatment
among those infected remains low in 2017, at 1.8% for HBV (4.5
million of the estimated 257 million infected) and 2.5% for HCV
(1.76 million treated among 71 million infected).1 The scaling up
of hepatitis testing and treatment will require comprehensive ser-
vice delivery models that include (1) simple and standardized
algorithms across the continuum of care; (2) integration of
hepatitis testing, care and treatment with other related services;
(3) strategies to strengthen linkage from testing to care, treatmentJHEP Reports 201and prevention; (4) decentralized services, supported by task-
sharing/shifting; (5) community engagement and peer support
to address stigma and discrimination, and reach vulnerable
or disadvantaged communities; (6) efficient procurement and
supply management of medicines and diagnostics; (7) data
systems to monitor the quality of individual care and the cascade
of care.23
Most countries lacked both baseline estimates and targets in
terms of incidence of infection or mortality reduction. The 2016
monitoring and evaluation framework for viral hepatitis B and
C outlines the chain of information required, from (i) context and
needs (i.e., mostly prevalence of infection) to (ii) input (i.e., infra-
structure), (iii) output and outcomes (i.e., prevention indicators
and indicators of the cascade of care) and (iv) impact (i.e., incidence
and mortality).9 Data systems needed to inform this framework
include: (1) surveillance for acute hepatitis, chronic infections and
sequelae; (2) programme data documenting prevention and treat-
ment, which for the latter includes the cascade of care.10 Collabora-
tions between viral hepatitis and other health programmes (e.g.,
immunization, communicable/non-communicable disease control,
infection control, harm reduction, HIV, tuberculosis, maternal and
child health) will be needed at the strategic, policy, technical,
implementation and data management level to ensure that strate-
gic information can be collected, transmitted, analysed and used
for action without creating new data systems.10,28
Our report suffers from a number of limitations. First, it is a
baseline analysis that is hard to compare with other sources
of data. This limits our capacity to validate our results. Second,
our analysis could not determine whether or not these plans
covered all the necessary elements or are in line with the
WHO framework.17 Third, some responses to the country pro-
files could have been made out of a desire to present an ideal
situation. As a consequence of these limitations, our report
may be overly optimistic. However, the increasing trend in
the development of national plans is consistent with that pre-
viously reported by the WHO in 2016.18,29 In conclusion,9 vol. 1 | 81–89 87
Research Articlecountries are making progress with respect to national hepati-
tis planning, but financing remains an issue. Scale-up of testing
and treatment has started, but it is still in its infancy in many
countries. Finally, the availability of strategic information to
assess the situation and guide elimination plans remains
limited. Based on these conclusions, we suggest governments,
in partnership with civil society and with support from WHO
and other key stakeholders, build upon the work done to estab-
lish national policies and plans and: (1) estimate the resource
needs to deliver a comprehensive response and increaseJHEP Reports 201investment through innovative financing27 (in the context of
universal health coverage); (2) build a stronger case for testing
and treatment, documenting the cost-effectiveness and savings
of these interventions; (3) strengthen the strategic information
needed to direct hepatitis elimination, in the context of inte-
grated systems that serve the broader health system. In 2018,
the WHO established a new Global Reporting System for Hepa-
titis that will continue to collect key policy uptake indicators,
along with indicators of the cascade of care, so that we can
follow-up on the future evolutions of these trends.30Financial support
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